Oncology Resource Group (ONCrg)
@onc-rg.bsky.social
Oncology Resource Group serves pharmaceutical and biotechnology developers worldwide by delivering best-in-class market planning and competitive intelligence reports.
We’ll be following how these subgroup analyses help define the role of PD-(L)1 x VEGF bispecifics in this dynamic and evolving space.
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
SITC 2025 – Oncology Resource Group
onc-rg.com
October 30, 2025 at 7:42 PM
We’ll be following how these subgroup analyses help define the role of PD-(L)1 x VEGF bispecifics in this dynamic and evolving space.
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
ONCrg SITC Conference Coverage details: onc-rg.com/conferences/...
#SITC2025 #NSCLC #ImmunoOncology #EGFR #LungCancerResearch #ClinicalTrials #ONCrg
Earlier HARMONi data (WCLC) left some uncertainty around both points so this next data look will be important.
Notably, WCLC, ESMO, and SITC 2025 have all featured ivonescimab late breaking abstracts, though ESMO featured ivonescimab data from a different NSCLC patient subset (1L squamous NSCLC).
Notably, WCLC, ESMO, and SITC 2025 have all featured ivonescimab late breaking abstracts, though ESMO featured ivonescimab data from a different NSCLC patient subset (1L squamous NSCLC).
October 30, 2025 at 7:42 PM
Earlier HARMONi data (WCLC) left some uncertainty around both points so this next data look will be important.
Notably, WCLC, ESMO, and SITC 2025 have all featured ivonescimab late breaking abstracts, though ESMO featured ivonescimab data from a different NSCLC patient subset (1L squamous NSCLC).
Notably, WCLC, ESMO, and SITC 2025 have all featured ivonescimab late breaking abstracts, though ESMO featured ivonescimab data from a different NSCLC patient subset (1L squamous NSCLC).
1️⃣ Whether the overall survival (OS) benefit seen in the Chinese HARMONi-A study translates to Western populations
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
October 30, 2025 at 7:42 PM
1️⃣ Whether the overall survival (OS) benefit seen in the Chinese HARMONi-A study translates to Western populations
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
1️⃣ Whether the overall survival (OS) benefit seen in the Chinese HARMONi-A study translates to Western populations
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
October 30, 2025 at 7:38 PM
1️⃣ Whether the overall survival (OS) benefit seen in the Chinese HARMONi-A study translates to Western populations
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
2️⃣ Whether the PD-(L)1 inhibitor component of ivonescimab adds meaningful efficacy in the patient subset
🚨 Which WCLC 2025 data are you most excited about? Vote in our poll or drop your thoughts below.
www.linkedin.com/posts/oncolo...
www.linkedin.com/posts/oncolo...
#wclc2025 #lungcancer #nsclc #sclc #pharmaci #medicalinsights #competitivestrategy | Oncology Resource Group
📢 Big news coming out of WCLC 2025!
The Plenary Sessions are packed with pivotal readouts that could reshape the lung cancer landscape.
👉 Which data are you most excited about? Vote in our poll or d...
www.linkedin.com
August 26, 2025 at 4:42 PM
🚨 Which WCLC 2025 data are you most excited about? Vote in our poll or drop your thoughts below.
www.linkedin.com/posts/oncolo...
www.linkedin.com/posts/oncolo...